Stanford University
Showing 161-180 of 269 Results
-
Kazuo Ando
Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine
BioBorn and raised in Japan, Dr. Ando received an MD-PhD degree from the Aichi Medical University. After anesthesia training, Dr. Ando came to Stanford to pursue clinical and basic research experience. During his postdoctoral fellowship in Dr. Gaudilliere's laboratory, Dr. Ando worked on publication of “A next-generation single-cell technology (mass cytometry) to study the feto-maternal immune system,” a project designed to evaluate the immune response associated with preterm birth. In addition, Dr. Ando performs research in Obstetric Anesthesia, such as respiratory monitoring after cesarean sections and labor satisfaction, to obtain clinical research experience and to understand the key differences in medicine between the United States and Japan.
After his postdoctoral fellowship, Dr. Ando has maintained his status as a researcher in Dr. Gaudilliere's laboratory, continuing work relating to pregnancy and preterm birth.
Dr. Ando divides his efforts between laboratory research and the clinic. -
Katrin Andreasson
Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences
Current Research and Scholarly InterestsOur research focuses on understanding how immune responses initiate and accelerate synaptic and neuronal injury in age-related neurodegeneration, including models of Alzheimer's disease and Parkinson's disease. We also focus on the role of immune responses in aggravating brain injury in models of stroke. Our goal is the identification of critical immune pathways that function in neurologic disorders and that can be targeted to elicit disease modifying effects.
-
Coley Andrews
Lecturer
BioColey Andrews is the Managing Member and co-founder of Pacific Lake Partners, a firm focused exclusively on the Search Fund model. Since co-founding Pacific Lake in 2009 with Search Fund pioneer Jim Southern, Coley has worked with over 200 search funds worldwide.
Coley is responsible for leading Pacific Lake’s growth to support the firm’s mission, which is to empower entrepreneurial CEO’s with resources and capital to buy and build extraordinary businesses. Pacific Lake has a team of 24 talented individuals, including successful former search fund CEOs, working full-time to support entrepreneurs.
Coley is a current or former board member of multiple search fund companies including Morningside Translations, FieldEdge, Ethos Risk Services, Intellitriage, Flint Group, Datacor, and Circle Surrogacy. Coley also is a current or former board observer at Vector Disease Control, Raptor Technologies, and Arizona College of Nursing.
Coley is a Lecturer at Stanford Graduate School of Business where he teaches two classes focused on managing growing enterprises as a young entrepreneurial leader.
Prior to forming Pacific Lake, Coley worked for Golden Gate Capital, a private equity firm in San Francisco, and in management consulting for The Parthenon Group. Coley graduated from Dartmouth College and has an MBA from Stanford’s Graduate School of Business. Coley lives with his family outside of Boston, MA. -
Jason Andrews
Professor of Medicine (Infectious Diseases)
Current Research and Scholarly InterestsOur laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.
-
Thomas P. Andriacchi
Professor of Mechanical Engineering and of Orthopaedic Surgery, Emeritus
Current Research and Scholarly InterestsProfessor Andriacchi's research focuses on the biomechanics of human locomotion and applications to medical devices, sports injury, osteoarthritis, the anterior cruciate ligament and low cost prosthetic limbs
-
Lay Teng Ang
Instructor, Institute for Stem Cell Biology and Regenerative Medicine
BioAs a stem cell biologist, I aim to understand the mechanisms through which stem cells differentiate into progressively specialized cell types and to harness this knowledge to artificially generate pure populations of desired cell types from stem cells. My work over the past ten years has centered on pluripotent stem cells (PSCs, which include embryonic and pluripotent stem cells), which can generate any of the hundreds of diverse cell types in the body. However, it has been notoriously challenging to guide PSCs to differentiate into a pure population of a given cell type. Current differentiation strategies typically generate heterogeneous cell populations unsuitable for basic research or clinical applications. To address this challenge, I mapped the cascade of branching lineage choices through which PSCs differentiate into various endodermal and mesodermal cell types. I then developed effective methods to differentiate PSCs into specific lineages by providing the extracellular signal(s) that specify a given lineage while inhibiting the signals that induce the alternate fate(s), enabling the generation of highly-pure human heart and bone (Loh & Chen et al., 2016; Cell) and liver (Loh & Ang et al., 2014; Cell Stem Cell) from PSCs. My laboratory currently focuses on differentiating human PSCs into liver progenitors (Ang et al., 2018; Cell Reports) and blood vessel cells (Ang et al., 2022; Cell).
I earned my Ph.D. jointly from the University of Cambridge and A*STAR and was subsequently appointed as a Research Fellow and, later, a Senior Research Fellow at the Genome Institute of Singapore. I then moved my laboratory to Stanford University as a Siebel Investigator and Instructor at the Stanford Institute for Stem Cell Biology & Regenerative Medicine. My laboratory has been supported by the Siebel Investigatorship, California Institute for Regenerative Medicine, and other sources. -
Michael Angelo
Associate Professor of Pathology
BioMichael Angelo, MD PhD is a board-certified pathologist and assistant professor in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. In recognition of this achievement, Dr. Angelo received the NIH Director’s Early Independence award in 2014. His lab has since used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune, stromal, and tumor cells within the tumor microenvironment in triple negative breast cancer. These findings were found to be predictive of single cell expression of several immunotherapy drug targets and of 10-year overall survival. This effort has led to ongoing work aimed at elucidating structural mechanisms in the TME that promote recruitment of cancer associated fibroblasts, tumor associated macrophages, and extracellular matrix remodeling. Dr. Angelo is the recipient of the 2020 DOD Era of Hope Award and a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.
-
Timothy Angelotti MD, PhD
Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly InterestsMy research efforts are focused on investigating the pharmacological and physiological interface of the autonomic nervous system with effector organs. Utilizing molecular, cellular, and electrophysiological techniques, we are examining alpha2 adrenergic receptor function in cultured sympathetic neurons. Future research aims will be directed toward understanding neurotransmitter release in general.
-
Martin S. Angst
Professor of Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly InterestsOur laboratory studies biological and clinical determinants of human resilience using surgery as an injury model.
-
Subini Ancy Annamma
Associate Professor of Education
BioPrior to her doctoral studies, Subini Ancy Annamma was a special education teacher in both public schools and youth prisons. Currently, she is an Associate Professor in the Graduate School of Education at Stanford University. Her research critically examines the ways students are criminalized and resist that criminalization through the mutually constitutive nature of racism and ableism, how they interlock with other marginalizing oppressions, and how these intersections impact youth education trajectories in urban schools and youth prisons. Further, she positions students as knowledge generators, exploring how their narratives can inform teacher and special education. Dr. Annamma’s book, The Pedagogy of Pathologization (Routledge, 2018) focuses on the education trajectories of incarcerated disabled girls of color and has won the 2019 AESA Critic’s Choice Book Award & 2018 NWSA Alison Piepmeier Book Prize. Dr. Annamma is a past Ford Postdoctoral Fellow, AERA Division G Early Career Awardee, Critical Race Studies in Education Associate Emerging Scholar recipient, Western Social Science Association's Outstanding Emerging Scholar, and AERA Minority Dissertation Awardee. Dr. Annamma’s work has been published in scholarly journals such as Educational Researcher, Teachers College Record, Review of Research in Education, Teaching and Teacher Education, Theory Into Practice, Race Ethnicity and Education, Qualitative Inquiry, among others.
-
Justin P. Annes M.D., Ph.D.
Associate Professor of Medicine (Endocrinology)
On Partial Leave from 05/01/2024 To 02/28/2025Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
DIABETES
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families. -
Arash Anoshiravani
Clinical Associate Professor, Pediatrics - Adolescent Medicine
Current Research and Scholarly InterestsResearch interests include high-risk youth, adolescent health services, and the juvenile justice system.
-
David Ansel
Clinical Associate Professor, Pediatrics
BioI graduated from UCLA (now Geffen) School of Medicine, did my pediatrics residency at Columbia-Presbyterian in NYC, followed by a clinical fellowship in developmental (what was then called an “ambulatory”) pediatrics at Boston Children’s Hospital. The first 28 years of my career were spent in clinical practice combining both DBP and primary care (the latter focused on serving CSHCN). During those years I was involved in numerous divide-bridging efforts - including programs to coordinate inpatient & outpatient medicine, connect tertiary & primary care, and promote teamwork between pediatricians, psychologists, nurse practitioners, and other community partners. I founded my own solo practice in 1989 and managed its growth to an 8-provider group over the next 25 years. Our practice was a founding member of the PPOC and I served on its board of directors for 6 years. The PPOC is one of the largest pediatric IPA’s in the country, with >200 member providers affiliated with Boston Children's Hospital. Over the years we were involved in groundbreaking QI initiatives including those involving asthma, weight, and ADHD management; medical home; and behavioral health integration with primary care.
I’m now well into my career's “second act” on the clinician-educator track here at Stanford. I'm proud to have piloted our division's primary care initiative (DBPCI) and am now in the process of planning for a second phase thereof, hoping to make improved collaboration between DBP and primary care more available to more patients. I also pioneered the use of telehealth in our division, and then helped guide its sudden widespread adoption by my peers during the COVID-19 crises. Looking forward, I expect what we have learned during the pandemic will inform what we do for DBPCI 2.0. -
anthony lising antonio
Associate Professor of Education
Current Research and Scholarly InterestsTransitions to postsecondary education; racial, ethnic, and religious minority college student development.
